Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics

With antimicrobial resistance to current drugs steadily rising, the development of new antibiotics with novel mechanisms of action has become an imperative. The majority of life-threatening infections worldwide are caused by "ESKAPE" pathogens which are encountered in more than 40% of hosp...

Full description

Bibliographic Details
Other Authors: Bionda, Nina.
Format: Others
Language:English
Published: Florida Atlantic University
Subjects:
Online Access:http://purl.flvc.org/FAU/3360768
id ndltd-fau.edu-oai-fau.digital.flvc.org-fau_4085
record_format oai_dc
spelling ndltd-fau.edu-oai-fau.digital.flvc.org-fau_40852019-07-04T03:54:01Z Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics Bionda, Nina. Text Electronic Thesis or Dissertation Florida Atlantic University English xv, 197 p. : ill. (some col.) electronic With antimicrobial resistance to current drugs steadily rising, the development of new antibiotics with novel mechanisms of action has become an imperative. The majority of life-threatening infections worldwide are caused by "ESKAPE" pathogens which are encountered in more than 40% of hospital-acquired infections, and are resistant to the majority of commonly used antibiotics. Naturally occurring cyclic depsipeptides, microbial secondary metabolites that contain one or more ester bonds in addition to amide bonds, have emerged as an important source of pharmacologically active compounds or lead structures for the development of novel antibiotics. Some of those peptides are either already marketed (daptomycin) or in advanced stages of clinical development (ramoplanin). Structurally simple, yet potent, fusaricidin/LI-F and lysobactin families of naturally occurring antibiotics represent particularly attractive candidates for the development of new antibacterial agents capable of overco ming infections caused by multidrug-resistant bacteria. These natural products exhibit potent antimicrobial activity against a variety of clinically relevant fungi and Gram-positive bacteria. Therefore, access to these classes of natural products and their synthetic analogs, combined with elucidation of their mode of action represent important initial steps toward full exploitation of their antmicrobial potential. This dissertation describes a general approach toward the solid-phase synthesis of fusaricidin/LI-F and lysobactin analogs and an extensive structure-activity relationship (SAR) study. We have devised a simple and robust preparation strategy based on standard Fmoc solid-phase peptide synthesis protocols. The SAR study revealed key structural requirements for fusaricidin/LI-F and related cyclic lipopeptides antibacterial activity, including the presence of the guanidino moietly at the end of the lipidic tail, hydrophobic amino acid residues, and peptide conformation Moreover, substitution of the ester bond with an amide bond significantly improved stability under physiologically relevant conditions and reduced toxicity. In addition, we have shown that these antibacterial peptides exert their mode of action via a novel mechanism, which invloves bacterial membrane interactions, followed by peptide internalization. Altogether, the research described in this dissertation demonstrates that new antibiotics derived from fusaricidin/LI-F natural products, have the potential to meet the challenge of antibiotic resistance in Gram-positive bacteria. by Nina Bionda. Thesis (Ph.D.)--Florida Atlantic University, 2013. Includes bibliography. Mode of access: World Wide Web. System requirements: Adobe Reader. Microbial peptides Drugs--Design Peptides--Therapeutic use Genetic engineering Antibacterial agents Peptide antibiotics--Research--Methodology Peptide antibiotics--Analysis http://purl.flvc.org/FAU/3360768 849647426 3360768 FADT3360768 fau:4085 Charles E. Schmidt College of Science Department of Chemistry and Biochemistry http://rightsstatements.org/vocab/InC/1.0/ https://fau.digital.flvc.org/islandora/object/fau%3A4085/datastream/TN/view/Cyclic%20lipodepsipeptides%20as%20lead%20structures%20for%20the%20discovery%20of%20new%20antiobiotics.jpg
collection NDLTD
language English
format Others
sources NDLTD
topic Microbial peptides
Drugs--Design
Peptides--Therapeutic use
Genetic engineering
Antibacterial agents
Peptide antibiotics--Research--Methodology
Peptide antibiotics--Analysis
spellingShingle Microbial peptides
Drugs--Design
Peptides--Therapeutic use
Genetic engineering
Antibacterial agents
Peptide antibiotics--Research--Methodology
Peptide antibiotics--Analysis
Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
description With antimicrobial resistance to current drugs steadily rising, the development of new antibiotics with novel mechanisms of action has become an imperative. The majority of life-threatening infections worldwide are caused by "ESKAPE" pathogens which are encountered in more than 40% of hospital-acquired infections, and are resistant to the majority of commonly used antibiotics. Naturally occurring cyclic depsipeptides, microbial secondary metabolites that contain one or more ester bonds in addition to amide bonds, have emerged as an important source of pharmacologically active compounds or lead structures for the development of novel antibiotics. Some of those peptides are either already marketed (daptomycin) or in advanced stages of clinical development (ramoplanin). Structurally simple, yet potent, fusaricidin/LI-F and lysobactin families of naturally occurring antibiotics represent particularly attractive candidates for the development of new antibacterial agents capable of overco ming infections caused by multidrug-resistant bacteria. These natural products exhibit potent antimicrobial activity against a variety of clinically relevant fungi and Gram-positive bacteria. Therefore, access to these classes of natural products and their synthetic analogs, combined with elucidation of their mode of action represent important initial steps toward full exploitation of their antmicrobial potential. This dissertation describes a general approach toward the solid-phase synthesis of fusaricidin/LI-F and lysobactin analogs and an extensive structure-activity relationship (SAR) study. We have devised a simple and robust preparation strategy based on standard Fmoc solid-phase peptide synthesis protocols. === The SAR study revealed key structural requirements for fusaricidin/LI-F and related cyclic lipopeptides antibacterial activity, including the presence of the guanidino moietly at the end of the lipidic tail, hydrophobic amino acid residues, and peptide conformation Moreover, substitution of the ester bond with an amide bond significantly improved stability under physiologically relevant conditions and reduced toxicity. In addition, we have shown that these antibacterial peptides exert their mode of action via a novel mechanism, which invloves bacterial membrane interactions, followed by peptide internalization. Altogether, the research described in this dissertation demonstrates that new antibiotics derived from fusaricidin/LI-F natural products, have the potential to meet the challenge of antibiotic resistance in Gram-positive bacteria. === by Nina Bionda. === Thesis (Ph.D.)--Florida Atlantic University, 2013. === Includes bibliography. === Mode of access: World Wide Web. === System requirements: Adobe Reader.
author2 Bionda, Nina.
author_facet Bionda, Nina.
title Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
title_short Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
title_full Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
title_fullStr Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
title_full_unstemmed Cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
title_sort cyclic lipodepsipeptides as lead structures for the discovery of new antiobiotics
publisher Florida Atlantic University
url http://purl.flvc.org/FAU/3360768
_version_ 1719219191458824192